CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini

Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated dise

Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-license

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin

CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therap

LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Comp

Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding

Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today a

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK

https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), includ

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clini

Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Fr

CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin

Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3

Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO - Get Free Report) crossed below its two hundred da

CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals

Gainers

  During Wednesday's session, 340 companies made new 52-week lows.

  On Tuesday, 951 companies hit new 52-week lows.